Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vanessa Dalton

Pediatrics Lubbock, TX Medical Doctor

NPI 1689837486 CMS profile 76996

9812 Slide Rd, Suite 2100, Lubbock, TX 79424

Open in the dashboard

General payments

$2,767

151 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vanessa Dalton of Lubbock, TX is reported in the CMS Open Payments database as having received $2,767 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $820 49
2024 General $787 41
2023 General $552 29
2022 General $221 11
2021 General $315 17
2020 General $48 3
2019 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vanessa Dalton
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Vanessa Dalton were reported at $820. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Vanessa Dalton Pediatrics median Middle half National median
2019 $25 $86 $31–$183 $163
2020 $48 $49 $22–$110 $114
2021 $315 $68 $27–$158 $132
2022 $221 $77 $30–$173 $149
2023 $552 $88 $33–$190 $160
2024 $787 $94 $34–$206 $164
2025 $820 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $848 46 payments
  2. Corium, Inc. $584 29 payments
  3. Ironshore Pharmaceuticals Inc. $497 32 payments
  4. Collegium Pharmaceutical, Inc. $173 10 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $130 7 payments
  6. Tris Pharma Inc $97 5 payments
  7. Sanofi Pasteur Inc. $64 3 payments
  8. Kowa Pharmaceuticals America, Inc. $62 4 payments
  9. GlaxoSmithKline, LLC. $61 4 payments
  10. Merck Sharp & Dohme Corporation $61 3 payments
  11. Other $191 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,767 151 payments
Products named General payments · program years 2019–2025
  1. Azstarys $584 29 payments
  2. Qelbree Viloxazine Hydrochloride $580 32 payments
  3. JORNAY PM Central Nervous System Stimulant $428 29 payments
  4. QELBREE Psychology $268 14 payments
  5. Jornay PM Adhd $173 10 payments
  6. VYVANSE $130 7 payments
  7. ZORYVE $62 4 payments
  8. PEDIARIX $61 4 payments
  9. VAXELIS $61 3 payments
  10. TRUMENBA $60 3 payments
  11. Other $584 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record